ARCHIVES

Capitol Hill: Trial Results Represent Culmination of Research, Klausner Tells House

This article is from The Cancer Letter archive.

Vol. 25 No. 11 | March 19, 1999

Download PDF Visit The Full Archive

Related Articles

ODAC Recommendation for Pertuzumab Signals FDA’s Resolve In Granting Accelerated Approvals

September 20, 2013

Phase III Tecemotide Trial Fails OS Endpoint; Second Trial Planned After Subgroup Analysis

December 27, 2013

First Lady Recalls 1992 Meeting With NBCC, Credits Group For Progress In Breast Cancer

May 8, 1998

AHCPR Funds Centers to Review Practice

July 4, 1997

FDA claims news coverage violated privacy of applicants for oncology job.

March 4, 2005

In Brief: Bernard Fisher Professorship Endowed By ICI Pharma; Brady Wins RSNA Medal

January 5, 1990